Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | QDPR | P09417 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.36 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19556453 | 0.76 | NLRP3 (0.43) | NLRP3MAPTKITHDAC4HDAC6 | |
| SCHEMBL22437148 | 0.74 | NLRP3 (0.42) | NLRP3MAPTPDE10AJAK1HDAC4 | |
| SCHEMBL19556316 | 0.74 | NLRP3 (0.42) | NLRP3MAPTPDE10AJAK1HDAC4 | |
| SCHEMBL13490356 | 0.73 | WNT3A (0.49) | WNT3ATRPV1MAPTNAMPTKIT | |
| SCHEMBL19556007 | 0.73 | NLRP3 (0.41) | NLRP3MAPTJAK2HDAC4HDAC6 | |
| SCHEMBL21678923 | 0.72 | NLRP3 (0.40) | NLRP3HDAC4HDAC6 | |
| SCHEMBL19556060 | 0.71 | REV1 (0.41) | NLRP3MAPTPRMT5 | |
| SCHEMBL31706099 | 0.70 | NLRP3 (0.39) | NLRP3HDAC4HDAC6 | |
| SCHEMBL19555807 | 0.70 | ADORA1 (0.41) | NLRP3MAPT | |
| SCHEMBL23294399 | 0.70 | QDPR (0.45) | QDPRMAPTPRMT5NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-109641854-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| US-10913727-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2021-02-09 | — | — | US | disclosed |
| CN-112204009-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-08 | — | — | CN | disclosed |
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| EP-3710428-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20190135772-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3452456-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017193063-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913727-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | NLRP3 1387/4885QDPR 4382/4885WNT3A 3835/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NLRP3 1387/4885QDPR 4382/4885WNT3A 3835/4885 |
| US-20190135772-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NLRP3 1387/4885QDPR 4382/4885WNT3A 3835/4885 |
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NLRP3 1387/4885QDPR 4382/4885WNT3A 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.